CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 enrolled
Drug / intervention
Cytarabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02121418
NCT02121418N/ACompleted

Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)

University of Washington·interventional·Posted Apr 23, 2014·Updated Apr 13, 2018

In Brief

A clinical study evaluating Cytarabine, Decitabine, and 1 other intervention for Chronic Myelomonocytic Leukemia-2 and 3 related conditions. Completed, enrolled 12 participants across 9 sites.

Detailed Summary

This clinical trial studies decitabine and cytarabine in treating older patients with newly diagnosed acute myeloid leukemia, myelodysplastic syndrome that is likely to come back or spread to other places in the body, or myeloproliferative neoplasm. Drugs used in chemotherapy, such as decitabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving decitabine and cytarabine may work better than standard therapies in treating cancers of the bone marrow and blood cells, such as acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasm.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 23, 2014
Enrollment StartJun 1, 2014
Primary CompletionFeb 8, 2017
Study CompletionFeb 14, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.2 years ago

Interventions

Cytarabinedrug

Given IV

Decitabinedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies